Novel Antimicrobials Recognized as a 'Major Shift' in Treating Drug-Resistant Gonorrhoea
The first new treatments for gonorrhoea in decades are being viewed as a "major milestone" in the fight against drug-resistant strains of the bacteria, according to health experts.
An International Health Concern
The sexually transmitted infection are escalating worldwide, with data suggesting more than 82 million instances annually. Particularly high rates are reported in Africa and countries within the World Health Organization's designated area, which encompasses China and Mongolia to New Zealand. Across England, cases have reached a record high, while infection numbers across Europe in 2023 were significantly elevated compared to the rates from 2014.
“The approval of novel therapies for gonorrhoea is an critical and opportune step in the context of rising global incidence, the spread of superbugs and the highly restricted therapeutic options presently on offer.”
Medical experts are particularly alarmed about the surge in treatment-resistant strains. The WHO has classified it as a "priority pathogen". Recent surveillance found that the effectiveness of primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.
Two New Therapies Gain Clearance
One new antibiotic, also known as a brand name, was approved by the US FDA in December for treating gonorrhoea. This disease can lead to significant complications, including infertility. Researchers hope that focused deployment of this new drug will help slow the development of resistance.
Gepotidacin, originating from the drugmaker GlaxoSmithKline, gained clearance in the same week. This drug, which is employed against urinary tract infections, was proven in research to be successful in treating drug-resistant strains of the gonorrhoea bacteria.
A Novel Partnership
Zoliflodacin emerged from a new, not-for-profit approach for drug creation. The non-profit organisation Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to develop it.
“This approval signifies a significant shift in the therapy of multidrug-resistant gonorrhoea, which previously has been evolving faster than medical innovation.”
Research Study Outcomes and Worldwide Availability
According to data published in a prominent scientific publication, zoliflodacin eradicated more than 90% of genital gonorrhoea infections. This puts it on an equal footing with the current standard treatment, which uses an injection and a pill. The study included over 900 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.
Under the terms of its development partnership, GARDP has the ability to make available and distribute the drug in numerous regions with limited resources.
Clinicians directly involved have shared optimism. Access to a one-pill regimen such as this is described as a "revolutionary step" for gonorrhoea control. This is deemed vital to lessen the impact of the infection for people and to prevent the spread of extremely resistant gonorrhoea worldwide.
